AtriCure (NASDAQ:ATRC) Price Target Raised to $45.00 at Oppenheimer

AtriCure (NASDAQ:ATRC - Free Report) had its price target hoisted by Oppenheimer from $36.00 to $45.00 in a research report released on Thursday,Benzinga reports. Oppenheimer currently has an outperform rating on the medical device company's stock.

Several other research firms have also issued reports on ATRC. Canaccord Genuity Group increased their price objective on AtriCure from $61.00 to $66.00 and gave the stock a "buy" rating in a research note on Thursday. UBS Group raised their price objective on shares of AtriCure from $35.00 to $40.00 and gave the stock a "buy" rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. increased their price target on AtriCure from $40.00 to $51.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 11th. Needham & Company LLC reiterated a "buy" rating and issued a $51.00 price objective on shares of AtriCure in a research report on Thursday. Finally, Stifel Nicolaus increased their target price on AtriCure from $36.00 to $48.00 and gave the stock a "buy" rating in a report on Thursday. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $51.56.

AtriCure Price Performance

NASDAQ:ATRC traded up $1.35 during mid-day trading on Thursday, hitting $40.94. The company's stock had a trading volume of 577,628 shares, compared to its average volume of 590,066. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13. The stock has a fifty day moving average of $35.76 and a 200-day moving average of $31.50. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -49.33 and a beta of 1.46. AtriCure has a fifty-two week low of $18.94 and a fifty-two week high of $43.11.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ATRC. Adage Capital Partners GP L.L.C. bought a new position in AtriCure in the fourth quarter valued at approximately $9,168,000. Kennedy Capital Management LLC lifted its stake in AtriCure by 29.8% in the fourth quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock valued at $22,999,000 after buying an additional 172,648 shares during the period. Marshall Wace LLP boosted its holdings in AtriCure by 37.1% during the fourth quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock worth $18,922,000 after buying an additional 167,476 shares during the last quarter. Oberweis Asset Management Inc. bought a new stake in shares of AtriCure in the 4th quarter valued at about $4,630,000. Finally, Assenagon Asset Management S.A. boosted its stake in AtriCure by 151.6% during the 3rd quarter. Assenagon Asset Management S.A. now owns 229,130 shares of the medical device company's stock worth $6,425,000 after acquiring an additional 138,046 shares during the last quarter. Institutional investors own 99.11% of the company's stock.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.